Table 1

 Psoriasiform lesions in patients receiving anti-tumour necrosis factor agents

F, female; M, male; TNF, tumour necrosis factor.
*Data available for only 22 patients.
Underlying disease
    Rheumatoid arthritis18
    Ankylosing spondylitis8
    Crohn’s disease1
    Ulcerative colitis1
    Behçet’s disease2
Disease duration (years)5–21
Age (years)*49.8 (11.6)
Sex*F 17, M 5
Anti-TNF agent
    Adalimumab8
    Etanercept8
    Infliximab14
Type of psoriasis
    Pustular psoriasis19
    Psoriasis vulgaris10
    Guttate psoriasis2
Nail involvement3/5 patients
Onset of psoriasis (weeks)
    Within 43
    5–127
    >1220
Skin biopsy15
Additional agents
    Leflunomide5
    Methotrexate6
    Azathiaprine2
    Sulfasalazine1
History of psoriasis6
Positive family history2
Resolution of psoriasis
    Resolution off anti-TNF4
    No resolution off anti-TNF1
    Resolution on anti-TNF2
    No resolution on anti-TNF23